Long Term Follow-Up Study for rAAV-GAD Treated Subjects

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01301573

Enrollment

Registered

2011-02-23

Start date

2011-01-31

Completion date

Unknown

Last updated

2012-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's Disease

Brief summary

The purpose of this observational study is the long term follow-up of Parkinson's patients who participated in a clinical trial in which they received AAV-GAD gene transfer into the subthalamic nucleus (STN) region of the brain. Patients will be followed once a year for up to five (5) years. The study will monitor and evaluate the long term effects of AAV-GAD and provide long term safety information.

Interventions

BIOLOGICALrAAV-GAD

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

30 Years to 90 Years

Healthy volunteers

Inclusion criteria

* Participated in a clinical trial where they received AAV-GAD * Able to give informed consent to participate in the study

Exclusion criteria

* Received Deep Brain Stimulation after receiving AAV-GAD * Received any experimental device in the brain after receiving AAV-GAD * Had any type of brain surgery after receiving AAV-GAD * Received any experimental therapy (drug or biologic) for Parkinson's disease or any other indication after receiving AAV-GAD

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026